Eric Fitzsimmons

4 days ago | brnw.ch | Eric Fitzsimmons

ALFRED LACKS CARTER JR. is on a mission to foster “health intelligence” in communities of color. Carter comes from a family where the importance of understanding your health care has a special resonance: His grandmother was Henrietta Lacks, a cervical cancer patient whose cells were harvested and cultured without her knowledge. Lacks’ cells, called HeLa cells after the first two letters of her first and last names, are still used in medical research.

2 weeks ago | cancertodaymag.org | Eric Fitzsimmons

Every week, the editors of Cancer Today magazine bring you the top news for cancer patients from around the internet. Stay up to date with the latest in cancer research and care by subscribing to our e-newsletter. Surgery is a staple of early-stage cancer care, but select patients whose cancer responds to immunotherapy may not need to undergo an operation, according to a presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.

2 weeks ago | brnw.ch | Eric Fitzsimmons

APPROXIMATELY 40% of people with cancer who receive immune checkpoint inhibitors will experience immune-related adverse events (irAEs), ranging from mild symptoms of fatigue and rash to life-threatening conditions that can lead to hospitalizations and even death.

2 weeks ago | brnw.ch | Eric Fitzsimmons

PATIENTS EXPERIENCED longer survival and more time without cancer progressing when doctors used both liquid biopsy and traditional biopsy on tumor tissue to select tailored treatment, according to findings from the ROME study. Though treatment based on biomarkers detected in either blood or tumor tissue, but not both, were also associated with higher survival than standard of care in some cases, the largest increase in survival was in patients where the results of both tests agreed.

2 weeks ago | cancertodaymag.org | Eric Fitzsimmons

PATIENTS EXPERIENCED longer survival and more time without cancer progressing when doctors used both liquid biopsy and traditional biopsy on tumor tissue to select tailored treatment, according to findings from the ROME study. Though treatment based on biomarkers detected in either blood or tumor tissue, but not both, were also associated with higher survival than standard of care in some cases, the largest increase in survival was in patients where the results of both tests agreed.